Antag Therapeutics jagter investering på 100 mio på biotekmesse

Alexander Sparre-Ulrich fra biotekselskabet Antag Therapeutics benytter kongressen Bio-Europe i København til at lede efter 100 mio. kr. til selskabets forestående kliniske studier.

Alexander Sparre-Ulrich, stifter og adm. direktør i Antag Therapeutics. | Photo: Giulia Mangione

Alexander Sparre Ulrich, der er adm. direktør i Antag Therapeutics, har tænkt sig at udnytte chancen for at møde tusindvis af investorer og biotekfolk på Bio-Europe-kongressen, som løber af stablen netop nu i Bella Center i København.

Han jagter en investering på 100 mio. kr. (15 mio. dollar), og her er det oplagt at lede blandt kongressens deltagere, siger han.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Why do Nordic funds have so few female portfolio managers?

Only 16 percent of fund managers in Sweden are women. The figure is 11 percent in Finland, while just 6 percent of fund managers in Denmark and Norway are female. AMWatch has talked to four Nordic women in finance in search of answers regarding this imbalance and hear about their career experiences. 

Fidelity plans to halve CO2 in investment portfolios by 2030

Fidelity International's target will initially be limited to portfolio companies' direct emissions and those that stem from energy the company buys, so-called Scope 1 and Scope 2 emissions. The manager intends to add Scope 3 emissions once it has access to better data.

Related articles

Trial banner

Latest news


Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch